A CRISPR functional genomic screen revealed that FGFR signaling contributed to the resistance of the EGFR gatekeeper mutation (EGFR-T790M) to EGFR inhibition in EGFR-driven non-small cell lung cancer [85]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.